|
1.
|
|
11 p, 726.2 KB |
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ;
Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ;
Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ;
Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ;
Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ;
Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ;
Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ;
Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ;
Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ;
Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 -  10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340
|
|
|
2.
|
|
9 p, 1.3 MB |
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set
/
Grothey, Axel (Mayo Clinic) ;
Yoshino, Takayuki (National Cancer Center Hospital East) ;
Bodoky, Gyorgy (St László Hospital (Hongria)) ;
Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ;
García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ;
Li, Li (Eli Lilly and Company) ;
Lipkovich, Olga (Eli Lilly and Company) ;
Hsu, Yanzhi (Eli Lilly and Company) ;
Sashegyi, Andreas (Eli Lilly and Company) ;
Ferry, David (Eli Lilly and Company) ;
Nasroulah, Federico (Eli Lilly Argentina) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)
|
|
|
3.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D. C. (The West Clinic, Memphis, USA) ;
Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A. (Mayo Clinic, Phoenix, USA) ;
O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ;
Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
4.
|
|
8 p, 590.0 KB |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
/
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ;
Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ;
Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Bodoky, G. (St László Hospital (Hongria)) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ;
Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ;
Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
